DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jacqueline Miller - 3 Dado Ruvic - 2 Moderna - 2 BioNTech - 2 Patrick Wingrove - 2 Bill Berkrot - 2 Dr - 1 Debra Houry - 1
Top related locs:
Switzerland South Africa Israel Denmark U.S Britain New York United States
Top related orgs:
CDC - 3 REUTERS - 2 World Health Organization - 2 WHO - 2 U.S . Centers for Disease Control - 2 Prevention - 2 ” Moderna - 2 Omicron - 2

Search resuls for: "Jacqueline Miller"


4 mentions found


☆ Many women still face barriers to getting regular mammograms, CDC study finds
  + stars: | 2024-04-09 | by ( Mira Cheng | ) edition.cnn.com   time to read: +5 min
Research shows that Black women and women of lower socioeconomic status are more likely to die from breast cancer. The earlier breast cancer is caught, the easier it is to treat, according to the National Breast Cancer Foundation. Routine screening mammograms have been shown to reduce breast cancer deaths by 22%, Houry said in a news conference. However, these new findings show that other health-related social needs also play a role, Miller said. “Health care providers can now assess whether women have health-related social needs and help women get the services they need.
Persons: Dr, Debra Houry, Houry, Jacqueline Miller, Miller, ” Miller, Sanjay Gupta, Lisa C, Richardson, ” Houry, “, ” Organizations: CNN, Centers for Disease Control, Health, Research, CDC, National Breast Cancer Foundation, US Preventive Services Task Force, Medicare, Services, CNN Health, CDC’s Division of Cancer Prevention Locations: United States, Rhode Island, Wyoming, CDC’s
☆ Moderna says updated COVID vaccine is effective against newer variant
  + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +2 min
[1/2] A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsSept 6 (Reuters) - Moderna (MRNA.O) on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the dominant variant through most of 2023 and the target of the updated shots. Moderna said it had shared the new finding on its vaccine with regulators and submitted it for peer review publication. European regulators have since backed the Pfizer/BioNTech shot, with Britain's Medicines and Healthcare products Regulatory Agency approving the vaccine on Tuesday, but have yet to make any announcements on Moderna’s updated vaccine.
Persons: Dado Ruvic, Jacqueline Miller, Moderna, COVID, BioNTech, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, CDC, Omicron, U.S . Food, Drug Administration, Pfizer, Moderna, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: The Massachusetts, Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York
☆ Moderna, Pfizer say updated COVID shots generate strong response vs newer variant
  + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +3 min
Moderna said its shot generated an 8.7-fold increase in neutralizing antibodies against BA.2.86 compared with an untreated natural antibody response in clinical trials in humans. Pfizer said its updated vaccine with partner BioNTech (22UAy.DE) elicited a strong antibody response against BA.2.86 in a preclinical study in mice. Moderna, Pfizer/BioNTech and relative newcomer to the COVID vaccine market Novavax (NVAX.O) have created versions of their shots aimed at the XBB.1.5 subvariant, the dominant variant through most of 2023. Moderna shares were down 1.6% and Pfizer shares were off nearly 3% in afternoon trading. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the updated shots.
Persons: Moderna, Jacqueline Miller, BioNTech, Cowen, Tyler Van Buren, Dado Ruvic, Patrick Wingrove, Michael Erman, Bill Berkrot Organizations: Pfizer, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, Moderna, REUTERS, CDC, Omicron, U.S . Food, Drug Administration, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York, New Jersey
☆ Here’s what Pfizer and Moderna say is next for their Covid vaccines
  + stars: | 2023-05-22 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +9 min
Scott Olson | Getty ImagesThree years and billions of Covid vaccinations into the pandemic, Pfizer and Moderna say their work is far from over. Here's what Moderna and Pfizer say is next for their Covid shots. Annual Covid shotsPfizer and Moderna aim to keep up with a shift in the U.S. toward annual Covid shots rather than frequent booster doses. Miller, who helped lead the development of Moderna's Covid shot in 2020, said the advantages of using mRNA became evident earlier on in the pandemic. 'Next-generation' Covid shotsPfizer's and Moderna's Covid vaccines both deliver robust protection against the virus, but that immunity can start to fade after four to six months.
0 next >>
Total: 4